Supernus Pharmaceuticals Inc(SUPN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.91 | Insider Own | 6.34% | Shs Outstand | 58.2M | Perf Week | 2.33% |
| Market Cap | 2.37B | Forward P/E | 9.53 | EPS next Y | 79.45% | Insider Trans | - | Shs Float | 54.5M | Perf Month | -4.43% |
| Enterprise Value | 2.04B | PEG | 0.5 | EPS next Q | 0.49 | Inst Own | 102.17% | Short Float | 9.14% | Perf Quarter | -14.58% |
| Income | -0.11B | P/S | 2.86 | EPS this Y | -26.27% | Inst Trans | 2.16% | Short Ratio | 5.97 | Perf Half Y | -17.57% |
| Sales | 0.83B | P/B | 2.3 | EPS next 5Y | 18.99% | ROA | -7.82% | Short Interest | 4.99M | Perf YTD | -17.97% |
| Book/sh | 17.73 | P/C | 6.38 | EPS past 3/5Y | - | ROE | -10.49% | 52W High | -31.69% ($59.68) | Perf Year | -22.83% |
| Cash/sh | 6.39 | P/FCF | 126.32 | Sales past 3/5Y | 2.52% 6.68% | ROIC | -10.36% | 52W Low | 8.6% ($37.54) | Perf 3Y | 79.45% |
| Dividend Est. | - | EV/EBITDA | 54.42 | EPS Y/Y TTM | -264.42% | Gross Margin | 75.83% | Volatility(W/M) | 3.87% 4.15% | Perf 5Y | 35.76% |
| Dividend TTM | - | EV/Sales | 2.46 | Sales Y/Y TTM | 24.85% | Oper. Margin | -7.73% | ATR (14) | 1.66 | Perf 10Y | 97.43% |
| Dividend Ex-Date | - | Quick Ratio | 1.84 | EPS Q/Q | -353.07% | Profit Margin | -13.23% | RSI (14) | 44.84 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | Sales Q/Q | 32.4% | SMA20 | -2.15% ($41.67) | Beta | 0.52 | Target Price | $58.33 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/10/29 | SMA50 | -5.3% ($43.05) | Rel Volume | 1.11 | Prev Close | $40.7 |
| Employees | 778 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 24.52% 6.7% | SMA200 | -14.14% ($47.48) | Avg Volume(3M) | 0.83M | Price | $40.77 |
| IPO | 2012/5/1 | Option/Short | Yes/Yes | Trades | 6381 | Volume | 930,919 | Change | 0.17% |
A US specialty pharmaceutical company that develops and sells therapeutics for the central nervous system. It develops and commercializes treatments for central nervous system disorders such as epilepsy, attention deficit disorders, and Parkinson's disease, with exposure to product revenue and a drug development pipeline. The company operates in the central nervous system specialty pharmaceuticals sector.
Over the past 1 year, on the lower side
32% below its 1-year high.
Traded about as much as usual. That is 111% of its average volume.
Next earnings report: October 29
2 days to go.
SUPN has a sound balance sheet but weak earning power
Of every $100 in sales, $7.73 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -26.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $286. Peers typically go for $217. Compared with its own 4-year average, it is 21% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +35.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 102.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #21 of 83 in the industry
Based on market cap of $2B.
HCM#19 HUTCHMED (China) Limited ADR $2B PER 140.3 
BHC#20 Bausch Health Companies Inc $2B PER - SUPN#21 Supernus Pharmaceuticals Inc $2B PER - 
PBH#22 Prestige Consumer Healthcare Inc $2B PER 13.5 
PRGO#23 Perrigo Company plc $2B PER - 
FAQ
What kind of company is SUPN?
SUPN belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SUPN?
The market cap of SUPN is approximately $2.4B, ranking 1,897 within its sector.
What is the 52-week high and low for SUPN?
SUPN has recorded a 52-week high of $59.68 and a low of $37.54.
